PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: HIV
Challenges in the March Toward an AIDS-Free Generation
FDA’s approval of Truvada, a once-a-day oral combination of tenofovir and emtricitabine, for pre-exposure prophylaxis (or PrEP, a method for preventing HIV infection) arrived during a chorus of optimism surrounding major developments in the fight against AIDS.
HIV Market Banking on Fixed-Dose Treatments
The HIV markets are expected to grow for the next two years, but major patent expirations in the following years will have a huge impact on pharmaceutical sales by 2019, according to a new report by DataMonitor.
Antiretroviral sales in 2009 were estimated at $11.8 billion. While that figure is forecast to hit $14.4 billion in [...]
Posted in R&D Also tagged Antiretroviral drug, Atripla, Bristol Myers Squibb, Datamonitor, Fixed-dose combination, Gilead Sciences, Infectious disease Leave a comment
TB Alliance Trumpets New, Improved Drugs at World Health Assembly
Like polio and leprosy, developed countries have long since tamed tuberculosis. But even now, other parts of the world continue to struggle against the disease, with nearly all (98 percent) of TB’s 1.7 million worldwide deaths occurring in developing countries. TB’s high comorbidity with HIV infections has recently added another level of urgency to efforts [...]
Posted in Corporate Responsibility, Emerging Markets, Global, R&D Also tagged AIDS, Developing country, funding, Médicins Sans Frontières, neglected diseases, TB, TB Alliance, Tuberculosis, WHA, World Health Assembly Leave a comment
Gilead Making a Bundle
Gilead Sciences has once again proven that independent biotechs can innovate with the best of Big Pharma. The Silicon Valley company’s wizardry at weaving multiple drugs into a single weft enabled it to overthrow GlaxoSmithKline as king of HIV in 2007. Yesterday, at the 16th annual Congress of Retroviruses and Opportunistic Infections (CROI), the biotech [...]
Posted in Biotech, Emerging Markets, R&D Also tagged Biotech, Bristol Myers Squibb, Gilead Leave a comment
Medicines Patent Pool: Industry's Toe Still in the Water